Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardior Pharmaceuticals Demonstrates Reversal of Heart Failure with Lead Compound CDR132L","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardior Pharmaceuticals' CDR132 Demonstrates Improvement of Heart Function in Chronic Heart Failure Model","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Independent Peer-Reviewed Study Validates Therapeutic Mode of Action of Cardior's First-in-Class Heart Failure Program","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Inkef Capital","pharmaFlowCategory":"D","amount":"$76.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cardior Raises \u20ac64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding RNA-Based Lead Candidate CDR132L in Heart Failure Patients Post-Myocardial Infarction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$1,110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk to Acquire Cardior Pharmaceuticals and Strengthen Pipeline in Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Cardior Pharmaceuticals

    Menu

    Cardior Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Cardior Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Novo Nordisk to Acquire Cardior Pharmaceuticals and Strengthen Pipeline in Cardiovascular Disease

              Details:

              Through the acquisition, Novo Nordisk expand its pipeline in cardiovascular disease by including Cardior’s lead compound CDR132L, currently in phase 2 clinical development for the treatment of heart failure.

              Lead Product(s): CDR132L

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: CDR132L

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Novo Nordisk

              Deal Size: $1,110.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition March 25, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cardior Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding RNA-Based Lead Candidate CDR132L in Heart Failure Patients Post-Myocardi...

              Details:

              CDR132L is synthetic antisense oligonucleotide-based inhibitor directed against microRNA-132, that up-regulated in cardiac tissue of heart failure patients leading to expression of genes that are crucially involved in cardiac function thus leading to pathological remodeling.

              Lead Product(s): CDR132L

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: CDR132L

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cardior Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease

              Details:

              The Series B proceeds will be used to fund the late-stage clinical development of Cardior’s lead program, CDR132L and the expansion of the company’s earlier-stage pipeline.

              Lead Product(s): CDR132L

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: CDR132L

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Inkef Capital

              Deal Size: $76.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing August 25, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cardior Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Independent Peer-Reviewed Study Validates Therapeutic Mode of Action of Cardior's First-in-Class Heart Failure Program

              Details:

              The recent peer-reviewed study confirms the therapeutic mode of action of Cardior´s lead program CDR132L. CDR132L blocks the naturally occurring microRNA miR-132 which, if overexpressed, is a key driver of heart failure.

              Lead Product(s): CDR132L

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: CDR132L

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cardior Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cardior Pharmaceuticals' CDR132 Demonstrates Improvement of Heart Function in Chronic Heart Failure Model

              Details:

              The study demonstrates that repeated treatment with its lead compound Cdr132 L is safe, improves cardiac function and reduces both ventricular as well as left atrial volumes in chronic heart failure.

              Lead Product(s): CDR132L

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: CDR132L

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 22, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cardior Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cardior Pharmaceuticals Demonstrates Reversal of Heart Failure with Lead Compound CDR132L

              Details:

              In the in vivo study, Cardior´s compound CDR132L effectively prevented maladaptive growth and remodeling and restored cardiac function in a dose-dependent manner.

              Lead Product(s): CDR132L

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 31, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY